Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tamuzimod (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Oppilan Pharma

Most Recent Events

  • 30 Apr 2026 Status changed from active, no longer recruiting to discontinued as the Induction and Long-Term Extension Periods were completed and analyzed as planned. The Sponsor decided to terminate clinical conduct in the Open-Label Extension Period. The decision to terminate the study was not due to safety concerns.
  • 27 Feb 2025 According to a Ventyx Biosciences media release, Publication of the tamuzimod Phase 2 induction data in Lancet (January 2025, doi:10.1016/S2468-1253(24)00386-8) highlighted robust clinical and endoscopic remission rates in patients treated with tamuzimod compared to placebo.
  • 15 Oct 2024 According to a Ventyx Biosciences media release, a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative colitis was presented on October 15, 2024 during the United European Gastroenterology (UEG) Week meeting in Vienna, Austria.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top